Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Sapirstein Insider Profile
4 Followers
James Sapirstein, CEO, Therapeutics Division at Adynxx, holds 3.48K shares in Onconetix (Ticker: ONCO), holds 35.82K shares in Entero Therapeutics (Ticker: ENTO), holds 492.82K shares in Hepion Pharmaceuticals (Ticker: HEPA).
James Sapirstein Adynxx (ADYX)CEO, Therapeutics Division
Adynxx (ADYX)
CEO, Therapeutics Division
Ranked #1,735 out of 99,797 Corporate Insiders
Profitable Transactions
7 out of 7 Profitable Transactions
Average Return
+77.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James Sapirstein holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jul 05, 2023 - Jul 05, 2024
Return:+96.40%
The most profitable trade made by James Sapirstein
James Sapirstein's Trading History
Adynxx
Jan 17, 2014
CEO, Therapeutics Division
Uninformative Sell
58.11K
$474.93
Hepion Pharmaceuticals
Jan 05, 2018
CEO, Director
Uninformative Buy
―
$241.48K
Renovaro Biosciences
―
Director
―
―
Entero Therapeutics
Jul 03, 2024
Chairman & CEO, Director
Informative Sell
1.38K
$22.56K
Marizyme
―
Interim CEO, Director
―
―
Onconetix
Sep 30, 2024
Director
Uninformative Buy
―
$1.20K
ZyVersa Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see James Sapirstein's performance on stock
You May Also Like
James Sapirstein insider profile FAQ
What is the percentage of profitable transactions made by James Sapirstein?
The percentage of profitable transactions made by James Sapirstein is 100%.
What is the average return per transaction made by James Sapirstein?
The average return per transaction made by James Sapirstein is 77.20%.
What stocks does James Sapirstein hold?
James Sapirstein holds: ADYX, HEPA, RENB, ENTO, MRZM, ONCO, ZVSA stocks.
What was James Sapirstein’s latest transaction?
James Sapirstein latest transaction was an Uninformative Buy of ―.
What was James Sapirstein's most profitable transaction?
James Sapirstein’s most profitable transaction was an Informative Sell of ENTO stock on July 5, 2023. The return on the trade was 96.40%.
What is James Sapirstein's role in Adynxx?
James Sapirstein's role in Adynxx is CEO, Therapeutics Division.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.